Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from P16CDKN2/INK4A

Current Biology

Volumn 6, Issue 1, 1996, Pages 84-91

  Fåhraeus, Robin ^a   Paramio, Jesús M ^a,b   Ball, Kathryn L ^a   Lain, Sonia ^a   Lane, David P ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b CIEMAT   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; ONCOPROTEIN; PEPTIDE; PROTEIN P16INK4A; PROTEIN SERINE THREONINE KINASE; RETINOBLASTOMA PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; CELL CYCLE; CELL CYCLE S PHASE; DRUG ANTAGONISM; METABOLISM; MOLECULAR GENETICS; PHOSPHORYLATION;

AMINO ACID SEQUENCE; CARRIER PROTEINS; CELL CYCLE; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASES; MOLECULAR SEQUENCE DATA; PEPTIDES; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RETINOBLASTOMA PROTEIN; S PHASE;

EID: 0029177397     PISSN: 09609822     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0960-9822(02)00425-6     Document Type: Article

References (31)

1. Weinberg R: The Retinoblastoma protein and cell cycle control. Cell 1995, 81:323-330.
2. 1 cyclin-dependent kinases. Genes Dev 1995, 9:1149-1163.
3. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis N, Ding W, et al.: Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet 1994, 8:22-26.
4. Hussussian CJ, Struewing JP, Goldstein AM, Higgans P, Ally DS, Shehan MD, et al.: Germline p16 mutations in familial melanoma. Nature Genet 1994, 8:15-21.
5. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, et al.: Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinomas. Nature Genet 1994, 8:27-31.
6. Schmidt E, Ichimura K, Reifenberger G, Collins VP: CDKN2 (p16/MTS1) gene deletion or cdk4 amplification occurs in the majority of glioblastoma. Cancer Res 1994, 54:6321-6324.
7. INK4 function. Nature Gen 1995, 10:114-116.
8. Herbert J, Cayvela JM, Berkeley J, Sigaux F: Candidate tumour suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T-cells but not from B-cells lineage acute lymphoblastic leukemias. Blood 1994, 84:4038-4044.
9. Einhom S, Heymal M, Rassol O, Liu Y, Grander D, Soderhall S: Molecular analysis and prognostic importance of p16 deletions in acute lymphocytic-leukemia. Blood 1994, 84:297.
10. He J, Allen J, Collins P, Allalunis-turner J, Godbout R, Day R, James D: CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion In glioma cell lines. Cancer Res 54:5804-5807.
11. Bates S, Peters G: Cyclin D1 as a cellular oncogene. Semin Cancer Biol 1995, 6:73-82.
12. Hunter T, Pines J: Cyclins and cancer II: Cyclin D and cdk inhibitors come of age. Cell 1994, 79:573-582.
13. Warbrick E, Lane DP, Glover DM, Cox L: A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21 and proliferating cell nuclear antigen. Curr Biol 1995, 5:275-282.
14. Pawson T, Schessinger J: SH2 and SH3 domains. Curr Biol 1993, 3:434-442.
15. Gibbs JB, Oliff A: Pharmaceutical research in molecular oncology. Cell 1994, 79:193-198.
16. Moodie SA, Wolfman A: The 3Rs of life: Ras, Raf and growth regulation. Trends Genet 1994, 10:44-48.
17. Rodriguez-Viciana P, Warne PH, Dhad R, Vanhaesebroeck B, Gout I, Fry MJ, et al.: Phosphatidylinositol 3-OH as a direct target of Ras. Nature 1994, 370:527-532.
18. INK4b is a potential effector of cell cycle arrest mediated by TGF-β. Nature 1994, 371:257-261
19. INK4/MTS2-related cdk6 inhibitor, correlates with wild-type Rb function. Genes Dev 1994, 8:2939-2952.
20. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/cdk4. Nature 1893, 366:704-707.
21. Hirai H, Roussel MF, Kato J, Ashmun RA, Sherr CJ: Novel INK4 proteins, p19 and p18, are specific inhibitors of cyclin D-dependent kineses cdk4 and cdk6. Mol Cell Biol 1995, 15:2672-2681.
22. INK4. Mol Cell Biol 1995, 15:2681-2688.
23. Koh J, Enders G, Dynlacht BD, Harlow E: Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 1996, 375:506-510.
24. Lukas J, Parry L, Aagard L, Mann J, Bartkova J, Strauss M, Bartek J: Retinoblastoma protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 1995, 375:503-506.
25. Serrano M, Gomez-Lahoz E, DePhino RA, Beach D, Bar-Sagi D: Inhibition of ras-induced proliferation and cellular transformation by p16. Science 1995, 267:249-252.
26. Derossi D, Joliot AH, Chassaing G, Prochiantz A: The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 1994, 269:10444-10450.
27. 1 cyclins and the cyclin-dependent protein kineses. Proc Natl Acad Sci USA 1993, 90:10315-10319.
28. Mittnacht S, Weinberg R: G1/S phosphorylation of the retinoblastoma protein is associated with altered affinity for the nuclear compartment Cell 1991, 65:381-393.
29. INK4/MTS1 tumour suppressor gene product EMBO J 1995, 14:503-511.
30. Bork P: Hundreds of ankyrin-like repeats in functionally diverse proteins: Mobile modules that cross phyla horizontally? Proteins 1993, 17:363-374.
31. Gibbs JB, Oliff A, Kohl NE: Famesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 1994, 77:175-178.